Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial (vol 8, e000891, 2020)

被引：0
|
作者：
Motzer, R. J.
Escudier, B.
McDermott, D. F.
机构：
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2021年 / 9卷 / 05期
关键词：
D O I：
10.1136/jitc-2020-000891corr1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Nivolumab plus cabozantinib (NIVO plus CABO) versus sunitinib (SUN) for advanced renal cell carcinoma (aRCC): Outcomes by sarcomatoid histology and updated trial results with extended follow-up of CheckMate 9ER.
    Motzer, Robert J.
    Choueiri, Toni K.
    Powles, Thomas
    Burotto, Mauricio
    Bourlon, Maria Teresa
    Hsieh, James J.
    Maruzzo, Marco
    Shah, Amishi Yogesh
    Suarez, Cristina
    Barrios, Carlos H.
    Richardet, Martin Eduardo
    Porta, Camillo
    Goh, Jeffrey C.
    Tomita, Yoshihiko
    Bedke, Jens
    Zhang, Joshua
    Simsek, Burcin
    Scheffold, Christian
    Gupta, Saurabh
    Apolo, Andrea B.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [22] Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial
    Powles, T.
    Burotto, M.
    Escudier, B.
    Apolo, A. B.
    Bourlon, M. T.
    Shah, A. Y.
    Suarez, C.
    Porta, C.
    Barrios, C. H.
    Richardet, M.
    Gurney, H.
    Kessler, E. R.
    Tomita, Y.
    Bedke, J.
    George, S.
    Scheffold, C.
    Wang, P.
    Fedorov, V.
    Motzer, R. J.
    Choueiri, T. K.
    ESMO OPEN, 2024, 9 (05)
  • [23] Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial
    Motzer, Robert J.
    Escudier, Bernard
    George, Saby
    Hammers, Hans J.
    Srinivas, Sandhya
    Tykodi, Scott S.
    Sosman, Jeffrey A.
    Plimack, Elizabeth R.
    Procopio, Giuseppe
    McDermott, David F.
    Castellano, Daniel
    Choueiri, Toni K.
    Donskov, Frede
    Gurney, Howard
    Oudard, Stephane
    Richardet, Martin
    Peltola, Katriina
    Alva, Ajjai S.
    Carducci, Michael
    Wagstaff, John
    Chevreau, Christine
    Fukasawa, Satoshi
    Tomita, Yoshihiko
    Gauler, Thomas C.
    Kollmannsberger, Christian K.
    Schutz, Fabio A.
    Larkin, James
    Cella, David
    McHenry, M. Brent
    Saggi, Shruti Shally
    Tannir, Nizar M.
    CANCER, 2020, 126 (18) : 4156 - 4167
  • [24] Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study
    Plimack, Elizabeth R.
    Powles, Thomas
    Stus, Viktor
    Gafanov, Rustem
    Nosov, Dmitry
    Waddell, Tom
    Alekseev, Boris
    Pouliot, Frederic
    Melichar, Bohuslav
    Soulieres, Denis
    Borchiellini, Delphine
    Mcdermott, Raymond S.
    Vynnychenko, Ihor
    Chang, Yen-Hwa
    Tamada, Satoshi
    Atkins, Michael B.
    Li, Chenxiang
    Perini, Rodolfo
    Molife, L. Rhoda
    Bedke, Jens
    Rini, Brian I.
    EUROPEAN UROLOGY, 2023, 84 (05) : 449 - 454
  • [25] Efficacy and safety of nivolumab plus ipilimumab (N plus I) versus sunitinib (S) for first-line treatment of patients with advanced sarcomatoid renal cell carcinoma (sRCC) in the phase 3 CheckMate 214 trial with extended 5-year minimum follow-up.
    Tannir, Nizar M.
    Signoretti, Sabina
    Choueiri, Toni K.
    McDermott, David F.
    Motzer, Robert J.
    George, Saby
    Powles, Thomas
    Donskov, Frede
    Tykodi, Scott S.
    Pal, Sumanta K.
    Gupta, Saurabh
    Lee, Chung-Wei
    McHenry, M. Brent
    Rini, Brian I.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [26] Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma (vol 8, e000391, 2020)
    Ascierto, P. A.
    Del Vecchio, M.
    Mackiewicz, A.
    Robert, Caroline
    Chiarion-Sileni, Vanna
    Arance, Ana
    Lebbe, Celeste
    Svane, Inge Marie
    McNeil, Catriona
    Rutkowski, Piotr
    Loquai, Carmen
    Mortier, Laurent
    Hamid, Omid
    Bastholt, Lars
    Dreno, Brigitte
    Schadendorf, Dirk
    Garbe, Claus
    Nyakas, Marta
    Grob, Jean-Jacques
    Thomas, Luc
    Liszkay, Gabriella
    Smylie, Michael
    Hoeller, Christoph
    Ferraresi, Virginia
    Grange, Florent
    Gutzmer, Ralf
    Pikiel, Joanna
    Hosein, Fareeda
    Simsek, Burcin
    Maio, Michele
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)
  • [27] Clinical Outcomes by Nephrectomy Status In METEOR, A Randomized Phase 3 Trial of Cabozantinib Versus Everolimus in Patients with Advanced Renal Cell Carcinoma
    Tannir, Nizar M.
    Powles, Thomas
    Escudier, Bernard
    Donskov, Frede
    Gruenwald, Viktor
    Sternberg, Cora N.
    Schmidinger, Manuela
    Schoeffski, Patrick
    Szczylik, Cezary
    Peltolta, Katriina
    Nosov, Dmitry
    Melichar, Bohuslav
    Clary, Douglas
    Scheffold, Christian
    Motzer, Robert J.
    Choueiri, Toni K.
    KIDNEY CANCER, 2020, 4 (01) : 29 - 39
  • [28] Nivolumab plus cabozantinib (N plus C) vs sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): Results from 55-month follow-up of the CheckMate 9ER trial
    Bourlon, Maria Teresa
    Escudier, Bernard
    Burotto, Mauricio
    Powles, Thomas
    Apolo, Andrea B.
    Shah, Amishi Yogesh
    Porta, Camillo
    Suarez, Cristina
    Barrios, Carlos H.
    Richardet, Martin
    Gurney, Howard
    Kessler, Elizabeth R.
    Tomita, Yoshihiko
    Bedke, Jens
    Wang, Fong
    Wang, Peter
    Panzica, Julie
    Fedorov, Viktor
    Motzer, Robert J.
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 362 - 362
  • [29] Cabozantinib exposure–response analysis for the phase 3 CheckMate 9ER trial of nivolumab plus cabozantinib versus sunitinib in first-line advanced renal cell carcinoma
    Benjamin Duy Tran
    Jing Li
    Neang Ly
    Raffaella Faggioni
    Lorin Roskos
    Cancer Chemotherapy and Pharmacology, 2023, 91 : 179 - 189
  • [30] Dual immune checkpoint inhibition in metastatic renal cell carcinoma Editorial re.: Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced RCC: extended 4-year follow-up of the phase III CheckMate 214 trial
    Schmidinger, M.
    Shariat, S. F.
    Fajkovic, H.
    ESMO OPEN, 2021, 6 (01)
12345